核心结合因子急性髓系白血病的治疗：为获得更好的长期结果而不断改进。
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
机构信息
Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):153-8. doi: 10.1016/j.clml.2012.11.006. Epub 2012 Dec 21.
Abstract
UNLABELLED
Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains.
BACKGROUND
Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement.
MATERIALS AND METHODS
We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts.
RESULTS
Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer.
CONCLUSIONS
Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
摘要
未注明
尽管被认为是预后良好的急性髓细胞白血病（AML），但核心结合因子 AML 的长期存活率仍有很大的提高空间。我们讨论了改善这类 AML 患者预后的治疗方法，以及可能有助于逐步提高疗效的现有/未来策略。
背景
尽管被认为是预后良好的急性髓细胞白血病（AML），但核心结合因子（CBF）AML 的长期存活率仍有很大的提高空间。
材料和方法
我们在 PubMed 上查阅了与 CBF AML 治疗相关的、可获得的相关英文文献。综述还包括会议摘要。
结果
巩固治疗中多周期高剂量阿糖胞苷可改善缓解持续时间，但更大的研究组报告称，5 年或更长时间的总生存率在 40%至 50%范围内。
结论
需要通过临床试验和风险适应方法，共同努力改善 CBF AML 的预后。
相似文献
1
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):153-8. doi: 10.1016/j.clml.2012.11.006. Epub 2012 Dec 21.
2
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Am J Hematol. 2014 Dec;89(12):1121-31. doi: 10.1002/ajh.23821. Epub 2014 Aug 27.
3
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Int J Hematol. 2021 Jun;113(6):851-860. doi: 10.1007/s12185-021-03099-6. Epub 2021 Mar 2.
4
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28.
5
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.
6
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Pediatr Blood Cancer. 2020 Dec;67(12):e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4.
7
Core binding factor acute myeloid leukemia.
Semin Oncol. 2008 Aug;35(4):410-7. doi: 10.1053/j.seminoncol.2008.04.011.
8
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
Blood Cancer J. 2021 Jun 16;11(6):114. doi: 10.1038/s41408-021-00503-6.
9
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Pediatr Blood Cancer. 2021 Jan;68(1):e28736. doi: 10.1002/pbc.28736. Epub 2020 Sep 29.
10
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Cancer. 2020 May 15;126(10):2183-2192. doi: 10.1002/cncr.32769. Epub 2020 Feb 26.
引用本文的文献
1
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy.
Haematologica. 2025 Mar 1;110(3):608-620. doi: 10.3324/haematol.2024.285448.
2
Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).
BMC Cancer. 2023 May 25;23(1):476. doi: 10.1186/s12885-023-10965-5.
3
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Am J Hematol. 2022 May;97(5):574-582. doi: 10.1002/ajh.26496. Epub 2022 Feb 22.
4
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR.
Exp Hematol Oncol. 2021 Feb 2;10(1):8. doi: 10.1186/s40164-021-00204-7.
5
Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML).
Front Oncol. 2019 Oct 4;9:1016. doi: 10.3389/fonc.2019.01016. eCollection 2019.
6
IL1RL1 is dynamically expressed on Cbfb-MYH11 leukemia stem cells and promotes cell survival.
Sci Rep. 2019 Feb 11;9(1):1729. doi: 10.1038/s41598-018-38408-3.
7
[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2019 Jan 14;40(1):52-57. doi: 10.3760/cma.j.issn.0253-2727.2019.01.010.
8
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e19-e25. doi: 10.1016/j.clml.2017.09.017. Epub 2017 Sep 25.
9
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Am J Hematol. 2017 Sep;92(9):845-850. doi: 10.1002/ajh.24782. Epub 2017 Jun 9.
10
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.
Leuk Res. 2014 Jul;38(7):773-80. doi: 10.1016/j.leukres.2014.04.001. Epub 2014 Apr 12.
本文引用的文献
1
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8.
2
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30.
3
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
4
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Leuk Res. 2011 Oct;35(10):1376-83. doi: 10.1016/j.leukres.2011.06.003. Epub 2011 Jun 28.
5
Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.
Bone Marrow Transplant. 2012 Apr;47(4):499-507. doi: 10.1038/bmt.2011.121. Epub 2011 Jun 6.
6
Cytarabine dose for acute myeloid leukemia.
N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.
7
Acute myeloid leukemia.
J Natl Compr Canc Netw. 2011 Mar;9(3):280-317. doi: 10.6004/jnccn.2011.0027.
8
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.
9
Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
J Clin Oncol. 2010 Aug 10;28(23):3724-9. doi: 10.1200/JCO.2010.28.6468. Epub 2010 Jul 12.
10
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Clin Transplant. 2011 Mar-Apr;25(2):308-16. doi: 10.1111/j.1399-0012.2010.01251.x.
Zotero 插件